Anti-CD7 CAR-T cell therapy (Antion Biosciences)

N/A

Report date: 2024/08/01 17:14:08

Base Information

Drug NameAnti-CD7 CAR-T cell therapy (Antion Biosciences)
Drug Alias NameAnti CD7 chimeric antigen receptor T cell therapy (Antion Biosciences)Allogeneic miCAR7 T-cells (Antion Biosciences)anti-CD7 CAR T-cells (Antion Biosciences)miCAR7 (Antion Biosciences)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD7
TargetsT-cell antigen CD7
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAntion Biosciences SA
China Registration ClassN/A

Develop Information

Active CompaniesAntion Biosciences SA
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A